Compare EFC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | OGN |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | EFC | OGN |
|---|---|---|
| Price | $12.70 | $8.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $14.55 | $11.75 |
| AVG Volume (30 Days) | 1.5M | ★ 5.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 12.32% | 0.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | $43.05 | $1.67 |
| P/E Ratio | ★ $9.50 | $11.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.28 | $5.69 |
| 52 Week High | $14.12 | $13.25 |
| Indicator | EFC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 70.76 |
| Support Level | $12.37 | $8.32 |
| Resistance Level | $14.00 | $9.79 |
| Average True Range (ATR) | 0.22 | 0.48 |
| MACD | 0.14 | 0.37 |
| Stochastic Oscillator | 94.72 | 91.56 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.